Lorlatinib in patients with previously treated ALK+ advanced non-small cell lung cancer: efficacy and safety
Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ( NSCLC ) continue to develop resistance and CNS metastases become more difficult to manage.
Lorlatinib, a potent brain-penetrant 3rd generation ALK/ROS1 tyrosine kinase inhibitor, has shown robust clinical activity in ALK+ or ROS1+ NSCLC patients, most of whom had CNS metastases and failed greater than or equal to 1 ALK tyrosine kinase inhibitor.
This ongoing phase 2 study enrolled 275 patients with ALK+ or ROS1+ advanced NSCLC ± CNS metastases in cohorts ( ALK: EXP 1–5; ROS1: EXP 6 ) based on prior treatment; starting dose was Lorlatinib 100 mg QD.
Antitumor activity ( by independent central review per RECIST 1.1 ), safety and biomarkers were evaluated.
In 198 ALK+ patients assessed for antitumor activity ( ITT population ) in pooled subgroups ( EXP 2–3A [ only prior Crizotinib ± chemotherapy ( CT ) ], EXP 3B [ only 1 prior 2nd gen ALK TKI ± CT ], and EXP 4–5 [ 2 or 3 prior ALK TKIs ± CT ] ), Lorlatinib led to rapid ( median time to response 1.4 months ) deep and durable systemic and intracranial ( IC ) responses.
Of a total 139 patients in EXP 3B + EXP 4–5, 62, 47 and 8 received Alectinib, Ceritinib and Brigatinib, respectively, as last ALK TKI prior to Lorlatinib.
The most common treatment-related adverse effects ( TRAEs ) and grade 3/4 TRAEs across all cohorts ( n=275 ) were hypercholesterolemia ( 84%/16% ) and hypertriglyceridemia ( 66%/16% ); 32% and 24% of patients had TRAEs that led to dose delays and reductions, respectively.
No treatment-related deaths occurred; TRAEs led to permanent discontinuation in 8 pts.
Antitumor activity was seen across a range of ALK resistance mutations, eg G1202R and G1202del.
In conclusion, Lorlatinib has shown clinically meaningful benefit in ALK+ NSCLC patients with greater than or equal to 1 prior ALK TKI and was generally tolerable with adverse effects managed by dose modification or supportive therapy. ( Xagena )
Source: American Society of Clinical Oncology - ASCO Meeting, 2018
Durable and potent LDL-cholesterol reduction with Inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Results from a prespecified analysis of pooled data from three phase III studies evaluating the safety and efficacy of Inclisiran,...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
Lorviqua for treatment of adult patients with ALK-positive advanced non-small cell lung cancer, previously treated with one or more ALK tyrosine kinase inhibitors: approved in European Union
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...
Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...
GLAGOV trial: lowering LDL cholesterol with Evolocumab, a PCSK9 inhibitor, impacts underlying atherosclerotic disease on top of optimized statin therapy
The phase 3 GLAGOV ( GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound )...
Heterozygous familial hypercholesterolemia: 63% of patients treated with Alirocumab no longer required apheresis
Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...
The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor...